Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2023 · 10-Q
Revenue$43.98M$43.98M+20.4% vs Q1 2022 Net Income$41.95M$41.95MN/M vs Q1 2022 EPS Diluted$2.33$2.33N/M vs Q1 2022 Operating Income$14,205,000+566.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$31,534,000−33.1% Margins · derivedOperating margin32.3%+26.5 pt vs Q1 2022
Net margin95.4%+137.5 pt vs Q1 2022
ended Mar 31, 2023 · filed May 8, 2023 · 38 d after period end